| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:11288928 | IVR | 1.5 mmol/kg | 1.5 mmol/kg | Decrease in T4 levels | Metabolic endocrine-mediated perturbations |
| IVR | 1.5 mmol/kg | 1.5 mmol/kg | Increased Alanine aminotransferase (ALT) levels | Hepatic endocrine-mediated perturbations | |
| IVR | 1.5 mmol/kg | 1.5 mmol/kg | Affects the biochemical composition of liver | Hepatic endocrine-mediated perturbations | |
| IVR | 1.5 mmol/kg | 1.5 mmol/kg | Decrease in T3/T4 ratio | Metabolic endocrine-mediated perturbations | |
| IVR | 1.5 mmol/kg | 1.5 mmol/kg | Increased calcium levels | Metabolic endocrine-mediated perturbations | |
| IVR | 1.5 mmol/kg | 1.5 mmol/kg | Decrease in T3 levels | Metabolic endocrine-mediated perturbations | |
| PMID:17160105 | IVR | 2.5 mg/kg | 2.5 mg/kg | Decreased Alkaline phosphatase (ALP) levels | Hepatic endocrine-mediated perturbations |
| IVR | 25 mg/kg | 25 mg/kg | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 25 mg/kg | 25 mg/kg | Changes in liver morphology | Hepatic endocrine-mediated perturbations | |
| IVR | 25 mg/kg | 25 mg/kg | Decreased Alkaline phosphatase (ALP) levels | Hepatic endocrine-mediated perturbations | |
| IVR | 25 mg/kg | 25 mg/kg | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg | 50 mg/kg | Decreased Alkaline phosphatase (ALP) levels | Hepatic endocrine-mediated perturbations | |
| IVR | 50 mg/kg | 50 mg/kg | Increased Alanine aminotransferase (ALT) levels | Hepatic endocrine-mediated perturbations | |
| IVR | 6 mg/kg | 6 mg/kg | Decreased Alkaline phosphatase (ALP) levels | Hepatic endocrine-mediated perturbations | |
| IVR | 50 mg/kg | 50 mg/kg | Changes in liver morphology | Hepatic endocrine-mediated perturbations | |
| IVR | 6 mg/kg | 6 mg/kg | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 50 mg/kg | 50 mg/kg | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 3 mg/kg | 3 mg/kg | Decreased Alkaline phosphatase (ALP) levels | Hepatic endocrine-mediated perturbations | |
| IVR | 1.5 mg/kg | - | No significant effects observed | - | |
| IVR | 100 mg/kg | 100 mg/kg | Alterations in thymocytes population | Immunological endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Alterations in splenocytes population | Immunological endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Changes in liver morphology | Hepatic endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Increased Alanine aminotransferase (ALT) levels | Hepatic endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Hematopietic carcinoma | Endocrine-mediated cancer;Immunological endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Decreased Alkaline phosphatase (ALP) levels | Hepatic endocrine-mediated perturbations | |
| IVR | 12 mg/kg | 12 mg/kg | Decreased Alkaline phosphatase (ALP) levels | Hepatic endocrine-mediated perturbations | |
| IVR | 12 mg/kg | 12 mg/kg | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| PMID:18383315 | IVR | 40 mg/kg/day | 40 mg/kg/day | Decreased prolactin levels | Reproductive endocrine-mediated perturbations |
| IVR | 40 mg/kg/day | 40 mg/kg/day | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Decreased Dihydroxytestosterone (DHT) levels | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg/day | - | No significant effects observed | - | |
| IVR | 30 mg/kg/day | - | No significant effects observed | - | |
| PMID:22127959 | IVR | 40 mg/kg/day | 40 mg/kg/day | Increase in T4 levels | Metabolic endocrine-mediated perturbations |
| IVR | 40 mg/kg/day | 40 mg/kg/day | Decreased prolactin levels | Reproductive endocrine-mediated perturbations | |
| IVR | 40 mg/kg/day | 40 mg/kg/day | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 40 mg/kg/day | 40 mg/kg/day | Decrease in TSH levels | Metabolic endocrine-mediated perturbations | |
| IVR | 40 mg/kg/day | 40 mg/kg/day | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 40 mg/kg/day | 40 mg/kg/day | Decreased prostate weights | Reproductive endocrine-mediated perturbations | |
| IVR | 40 mg/kg/day | 40 mg/kg/day | Increase in T3 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 10 mg/kg/day | 10 mg/kg/day | Increased FSH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg/day | 10 mg/kg/day | Decreased prolactin levels | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg/day | 10 mg/kg/day | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 30 mg/kg/day | 30 mg/kg/day | Increased FSH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 30 mg/kg/day | 30 mg/kg/day | Decreased prostate weights | Reproductive endocrine-mediated perturbations | |
| IVR | 30 mg/kg/day | 30 mg/kg/day | Increased weights of thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 30 mg/kg/day | 30 mg/kg/day | Decreased prolactin levels | Reproductive endocrine-mediated perturbations | |
| IVR | 30 mg/kg/day | 30 mg/kg/day | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| PMID:4035593 | IVR | 0.1 mg/fetus | 0.1 mg/fetus | Affects survival of live fetus | Reproductive endocrine-mediated perturbations |
| IVR | 1 mg/fetus | 1 mg/fetus | Affects developmental process | Developmental endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.